PharoahPDDayNEDuffyS. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer1997;71:800–809.
BerlinerJLFayAM. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Couns2007;16:241–260.
TrepanierAAhrensMMcKinnonW. Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. J Genet Couns2004;13:83–114.
SchneiderKAGarberJ. (Updated February 9 2010)Li-Fraumeni syndrome. InGeneReviews at GeneTests: Medical Genetics Information Resource (database online); CopyrightUniversity of WashingtonSeattle. 1997–2010. Available at: http://www.genetests.org. Accessed March 3 2010.
Brooks-WilsonARKaurahPSurianoG. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet2004;41:508–517.
KaurahPMacMillanABoydN. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA2007;297:2360–2372.
OliveiraCBordinMCGrehanN. Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat2002;19:510–517.
SimonRZhangX. On the dynamics of breast tumor development in women carrying germline BRCA1 and BRCA2 mutations. Int J Cancer2008;122:1916–1917.
BergmanAEinbeigiZOlofssonU. The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. Eur J Hum Genet2001;9:787–793.
CsokayBUdvarhelyiNSulyokZ. High frequency of germline BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res1999;59:995–998.
MikaelsdottirEKValgeirsdottirSEyfjordJERafnarT. The Icelandic founder mutation BRCA2 999del5: analysis of expression. Breast Cancer Res2004;6:R284–290.
Petrij-BoschAPeelenTvan VlietM. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet1997;17:341–345.
ToninPNMes-MassonAMFutrealPA. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet1998;63:1341–1351.
FordDEastonDFStrattonM. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet1998;62:676–689.
CipakLWatanabeNBesshoT. The role of BRCA2 in replication-coupled DNA interstrand cross-link repair in vitro. Nat Struct Mol Biol2006;13:729–733.
WoosterRNeuhausenSLMangionJ. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13Science1994;265:2088–2090.
AbeliovichDKaduriLLererI. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet1997;60:505–514.
Levy-LahadECataneREisenbergS. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet1997;60:1059–1067.
PetrucelliNDalyMBBars CulverJOFeldmanGL. (Updated June 19 2007). BRCA1 and BRCA2 hereditary breast/ovarian cancer. InGeneReviews at GeneTests: Medical Genetics Information Resource (database online); CopyrightUniversity of WashingtonSeattle. 1997–2010. Available at: http://www.genetests.org. Accessed March 3 2010.
AntoniouAPharoahPDNarodS. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet2003;72:1117–1130.
FinchABeinerMLubinskiJ. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA2006;296:185–192.
RischHAMcLaughlinJRColeDE. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet2001;68:700–710.
AtchleyDPAlbarracinCTLopezA. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol2008;26:4282–4288.
LakhaniSRReis-FilhoJSFulfordL. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res2005;11:5175–5180.
LakhaniSRVan De VijverMJJacquemierJ. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol2002;20:2310–2318.
YoungSRPilarskiRTDonenbergT. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer2009;9:86.
LiedeAKarlanBYNarodSA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol2004;22:735–742.
Lorenzo BermejoJHemminkiK. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing. Ann Oncol2004;15:1834–1841.
BeinerMEFinchARosenB. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol2007;104:7–10.
JazaeriAALuKSchmandtR. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog2003;36:53–59.
BjorgeTLieAKHovigE. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. Br J Cancer2004;91:1829–1834.
PressJZDe LucaABoydN. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer2008;8:17.
PalTPermuth-WeyJBettsJA. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer2005;104:2807–2816.
RischHAMcLaughlinJRColeDE. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst2006;98:1694–1706.
GaytherSARussellPHarringtonP. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet1999;65:1021–1029.
SekineMNagataHTsujiS. Localization of a novel susceptibility gene for familial ovarian cancer to chromosome 3p22-p25. Hum Mol Genet2001;10:1421–1429.
LynchHTCaseyMJSnyderCL. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol2009;3:97–137.
KauffNDMitraNRobsonME. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. J Natl Cancer Inst2005;97:1382–1384.
CouchFJFaridLMDeShanoML. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet1996;13:123–125.
FriedmanLSGaytherSAKurosakiT. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet1997;60:313–319.
American Chemical Society. What are the key statistics about breast cancer in men?Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_male_breast_cancer_28.asp. Accessed on March 3 2010.
GonzalezKDNoltnerKABuzinCH. Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol2009;27:1250–1256.
NicholsKEMalkinDGarberJE. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev2001;10:83–87.
SiddiquiROnelKFacioF. The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds. Fam Cancer2005;4:177–181.
BirchJMHartleyALTrickerKJ. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res1994;54:1298–1304.
KrutilkovaVTrkovaMFleitzJ. Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations. Eur J Cancer2005;41:1597–1603.
MalkinDLiFPStrongLC. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science1990;250:1233–1238.
LustbaderEDWilliamsWRBondyML. Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet1992;51:344–356.
ChompretAAbelAStoppa-LyonnetD. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet2001;38:43–47.
BirchJMBlairVKelseyAM. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene1998;17:1061–1068.
BougeardGSesboueRBaert-DesurmontS. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet2008;45:535–538.
GinsburgOMAkbariMRAzizZ. The prevalence of germline TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer2009;8:563–567.
NelenMRKremerHKoningsIB. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet1999;7:267–273.
PilarskiREngC. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet2004;41:323–326.
EngC. PTEN hamartoma tumor syndrome (PTHS). GeneReviews Web site. Available at: http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=phts#phts. Accessed March 3 2010.
SchafferJVKaminoHWitkiewiczA. Mucocutaneous neuromas: an underrecognized manifestation of PTEN hamartoma-tumor syndrome. Arch Dermatol2006;142:625–632.
Al-ThihliKPalmaLMarcusV. A case of Cowden's syndrome presenting with gastric carcinomas and gastrointestinal polyposis. Nat Clin Pract Gastroenterol Hepatol2009;6:184–189.
ZhouXPWaiteKAPilarskiR. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet2003;73:404–411.
AndresRHGuzmanRWeisJ. Lhermitte-Duclos disease with atypical vascularization—case report and review of the literature. Clin Neuropathol2009;28:83–90.
ButlerMGDasoukiMJZhouXP. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet2005;42:318–321.
HermanGEButterEEnrileB. Increasing knowledge of PTEN germline mutations: Two additional patients with autism and macrocephaly. Am J Med Genet2007;143:589–593.
VargaEAPastoreMPriorT. The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. Genet Med2009;11:111–117.
MarshDJCoulonVLunettaKL. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet1998;7:507–515.
MurffHJSpigelDRSyngalS. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA2004;292:1480–1489.
ColditzGAWillettWCHunterDJ. Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. JAMA1993;270:338–343.
SlatteryMLKerberRA. A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA1993;270:1563–1568.
ClausEBRischNThompsonWD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer1994;73:643–651.
AntoniouACHardyRWalkerL. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet2008;45:425–431.
SaslowDBoetesCBurkeW. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin2007;57:75–89.
BlumanLGRimerBKBerryDA. Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol1999;17:1040–1046.
BennettRLFrenchKSRestaRGDoyleDL. Standardized human pedigree nomenclature: update and assessment of the recommendations of the National Society of Genetic Counselors. J Genet Couns2008;17:424–433.
BennettRLSteinhausKAUhrichSB. Recommendations for standardized human pedigree nomenclature. Pedigree Standardization Task Force of the National Society of Genetic Counselors. Am J Hum Genet1995;56:745–752.
WeitzelJNLagosVICullinaneCA. Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA2007;297:2587–2595.
BodianCAPerzinKHLattesR. Lobular neoplasia. Long term risk of breast cancer and relation to other factors. Cancer1996;78:1024–1034.
OsborneMPHodaSA. Current management of lobular carcinoma in situ of the breast. Oncology (Williston Park)1994;8:45–49; discussion 49 53–44.
BeralVDollRHermonC. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet2008;371:303–314.
ChlebowskiRTHendrixSLLangerRD. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA2003;289:3243–3253.
RossouwJEAndersonGLPrenticeRL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA2002;288:321–333.
WeissLKBurkmanRTCushing-HaugenKL. Hormone replacement therapy regimens and breast cancer risk(1). Obstet Gynecol2002;100:1148–1158.
American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol2003;21:2397–2406.
RobsonMEStormCDWeitzelJ. American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol2010;28:893–901.
BougeardGBaert-DesurmontSTournierI. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet2006;43:531–533.
ChibonFPrimoisCBressieuxJM. Contribution of PTEN large rearrangements in Cowden disease: a multiplex amplifiable probe hybridisation (MAPH) screening approach. J Med Genet2008;45:657–665.
PalmaMDDomchekSMStopferJ. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Res2008;68:7006–7014.
WeitzelJNLagosVIHerzogJS. Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev2007;16:1615–1620.
OffitKLevranOMullaneyB. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst2003;95:1548–1551.
OffitKSagiMHurleyK. Preimplantation genetic diagnosis for cancer syndromes: a new challenge for preventive medicine. JAMA2006;296:2727–2730.
WarnerEPlewesDBHillKA. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA2004;292:1317–1325.
KriegeMBrekelmansCTBoetesC. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med2004;351:427–437.
LeachMOBoggisCRDixonAK. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet2005;365:1769–1778.
StoutjesdijkMJBoetesCJagerGJ. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst2001;93:1095–1102.
KuhlCKSchradingSLeutnerCC. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol2005;23:8469–8476.
Tilanus-LinthorstMVerhoogLObdeijnIM. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer2002;102:91–95.
EvansDGGaarenstroomKNStirlingD. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet2009;46:593–597.
WoodwardERSleightholmeHVConsidineAM. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG2007;114:1500–1509.
HartmannLCSchaidDJWoodsJE. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med1999;340:77–84.
HartmannLCSellersTASchaidDJ. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst2001;93:1633–1637.
Meijers-HeijboerHvan GeelBvan PuttenWL. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med2001;345:159–164.
RebbeckTRFriebelTLynchHT. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol2004;22:1055–1062.
van DijkSvan RoosmalenMSOttenWStalmeierPF. Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret. J Clin Oncol2008;26:2358–2363.
LevineDAArgentaPAYeeCJ. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol2003;21:4222–4227.
PiverMSJishiMFTsukadaYNavaG. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer1993;71:2751–2755.
Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer2000;83:1301–1308.
SatagopanJMBoydJKauffND. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res2002;8:3776–3781.
RebbeckTRKauffNDDomchekSM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst2009;101:80–87.
FinchAShawPRosenB. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol2006;100:58–64.
KauffNDSatagopanJMRobsonME. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med2002;346:1609–1615.
KemelYKauffNDRobsonME. Four-year follow-up of outcomes following risk-reducing salpingo-oophorectomy in BRCA mutation carriers [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 1013.
RebbeckTRLevinAMEisenA. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst1999;91:1475–1479.
EisenALubinskiJKlijnJ. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol2005;23:7491–7496.
KauffNDDomchekSMFriebelTM. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol2008;26:1331–1337.
PowellCBKenleyEChenLM. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol2005;23:127–132.
RebbeckTRFriebelTWagnerT. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol2005;23:7804–7810.
EisenALubinskiJGronwaldJ. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst2008;100:1361–1367.
ChlebowskiRTPrenticeRL. Menopausal hormone therapy in BRCA1 mutation carriers: uncertainty and caution. J Natl Cancer Inst2008;100:1341–1343.
GarberJEHartmanAR. Prophylactic oophorectomy and hormone replacement therapy: protection at what price?J Clin Oncol2004;22:978–980.
KingMCWieandSHaleK. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA2001;286:2251–2256.
McLaughlinJRRischHALubinskiJ. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol2007;8:26–34.
NarodSARischHMoslehiR. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med1998;339:424–428.
HaileRWThomasDCMcGuireV. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev2006;15:1863–1870.
NarodSADubeMPKlijnJ. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst2002;94:1773–1779.